Phospholipase A2 inhibitors in inflammation

Bibliography

• SERHAN CN, HAEGGSTROM JZ, LESLIE CC: Lipid mediator network in cell signalling: update and impact of cytokines. FASEB J. (1996) 10(10):1147–1158.
   Google Scholar
• HUANG YH, SCHAFER-ELINDER L, WU R, CLAESSON HE, FROSTEGARD J: Lysophosphatidylcholine (LPC) induces pro-inflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. an. Exp. Immunol. (1999) 116(2):326–331.
   Google Scholar
• RYBORG AK, DELEURAN B, SOGAARD HR, KRAGBALLE K: Intracutaneous injection of lysophosphatidylcholine induces skin inflammation and accumulation of leukocytes. Acta Berm. Venereal. (2000) 80(4):242–246.
   Google Scholar
• •References 2 and 3 confirm the pro-inflammatory qualities of the lysophospholipids.
   Google Scholar
• CONNOLLY S, ROBINSON DH: Patent update: inhibitors of the phospholipases A2. Expert Opin. Ther. Patents (1993) 3(8):1141–1155.
   Google Scholar
• CONNOLLY S, ROBINSON DH: The search for inhibitors of the phospholipase A2. Expert Opin. Ther. Patents (1995) 5(7):673–683.
   Google Scholar
• •References 4 and 5 are critical reviews of the PLA2 patent literature published between 1992 and 1995.
   Google Scholar
• TIBES U, FRIEBE WG: Phospholipase A2 inhibitors in development. Expert Opin. Investig. Drugs (1997) 6(3):279–298.
   PubMedGoogle Scholar
• MAYER RJ, MARSHALL LA: The therapeutic potential for phospholipase A2 inhibitors. Emerging Drugs (1998) 3(1):333–344.
   Google Scholar
• •References 6 to 7 are reviews about the development of phospholipase A2 inhibitors.
   Google Scholar
• WALLACH DE BROWN VJR: Studies onthe arachidonic acid cascade-I: Inhibition of phospholipase A2 in vitro and in vivo by several novel series of inhibitor compounds. Biochem. Pharmacy]. (1981) 30 (11) :1315–1324.
   Google Scholar
• KRAMER RM, HESSION C, JOHANSEN B etal.: Structure and properties of a human non-pancreatic phospholipase A2. J. Biol. Chem. (1989) 264(10):5768–5775.
   Google Scholar
• HARA S, KUDO I, CHANG HW, MATSUTA K, MIYAMOTO T, INOUE K: Purification and characterization of extracellular phospholipase A2 from human synovial fluid in rheumatoid arthritis. J. Biochem. (1989) 105(3):395–399.
   Google Scholar
• SEILHAMER JJ, PRUZANSKI W, VADAS P et al.: Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. _J. Biol. Chem. (1989) 264(10):5335–5338.
   Google Scholar
• CLARK JD, MILONA N, KNOPF JL: Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937. Proc. Natl. Acad. Sci. USA (1990) 87(19):7708–7712.
   Google Scholar
• GRONICH JH, BONVENTRE JV, NEMENOFF RA: Purification of a high-molecular-mass form of phospholipase A2 from rat kidney activated at physiological calcium concentrations. Biochem. J. (1990) 271(1):37–43.
   Google Scholar
• SIX DA, DENNIS EA: The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim. Biophys. Acta. (2000) 1488(1-2):1–19.
   PubMed Web of Science ®Google Scholar
• •Review of the classification of the PLA2.
   Google Scholar
• GELB MH, VALENTIN E, GHOMASHCHI F, LAZDUNSKI M, LAMBEAU G: Cloning and recombinant expression of a structurally novel human secreted phospholipase A2. _J. Biol. Chem. (2000) 275(51):39823–39826.
   Google Scholar
• WINSTEAD MV, BALSINDE J, DENNIS EA: Calcium-independent phospholipase A2: structure and function. Biochim. Biophys. Acta. (2000) 1488(1-2):28–39.
   PubMed Web of Science ®Google Scholar
• •Review of the calcium-independent PLA2.
   Google Scholar
• MAYER RJ, MARSHALL LA: New insights on mammalian phospholipase Ags); comparison of arachidonyl-selective and -nonselective enzymes. FASEB J. (1993) 7(2): 339–348.
   PubMed Web of Science ®Google Scholar
• LIN LL, LIN AY, KNOPF JL: Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proc. Nat. Acad. Sci. USA (1992) 89(13):6147–6151.
   Google Scholar
• UOZUMI N, KUME K, NAGASE T et al.: Role of cytosolic phospholipase A2 in allergic response and parturition. Nature (1997) 390:618–622.
   PubMed Web of Science ®Google Scholar
• BONVENTRE JV, HUANG Z, TAHERI MR etal.: Reduced fertility and post-ischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature (1997) 390:622–625.
   Google Scholar
• GIJON MA, SPENCER DM, SIDDIQI AR, BONVENTRE JV, LESLIE CC: Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. j Biol. Chem. (2000) 275(26):20146–20156.
   Google Scholar
• •References 18–21 provide stringent evidence for the important role of cPLA2 in the generation of pro-inflammatory lipid mediators.
   Google Scholar
• KENNEDY BP, PAYETTE P, MUDGETT J et al.: A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. (1995) 270(38):22378–22385.
   PubMed Web of Science ®Google Scholar
• BINGHAM CO 3rd, MURAKAMI M, FUJISHIMA H, HUNT JE, AUSTEN KF, ARM JP: A heparin-sensitive phospholipase A2 and prostaglandin endoperoxide synthase-2 are functionally linked in the delayed phase of prostaglandin D2 generation in mouse bone marrow-derived mast cells. J. Biol. Chem. (1996) 271(42):25936–25944.
   Google Scholar
• FOX N, SONG M, SCHREMENTI J et al.: Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A2 inhibitors. Eur. Pharmacol. (1996) 308(2):195–203.
   Google Scholar
• GRASS DS, FELKNER RH, CHIANG MY etal.: Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J. Clin. Invest. (1996) 97(10):2233–2241.
   Google Scholar
• MORGAN DW, ANDERSON CM, MEYERS KP: Recombinant human Type II phospholipase A2 lacks edema producing activity in rat. Eur. I Pharmacol. (1993) 235(1):45–50.
   Google Scholar
• MOUNIER C, VARGAFTIG BB, FRANKEN PA, VERHEIJ HM, BON C, TOUQUI L: Platelet secretory phospholipase A2 fails to induce rabbit platelet activation and to release arachidonic acid in contrast with venom phospholipases A2. Biochim. Biophys. Acta (1994) 1214(1):88–96.
   Google Scholar
• BEZZINE S, KODURI RS, VALENTINE etal.: Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells. J. Biol. Chem. (2000) 275(5):3179–3191.
   Google Scholar
• BUCKLAND AG, WILTON DC: The antibacterial properties of secreted phospholipases A2. Biochim. Biophys. Acta. (2000) 1488(1-2):71–82.
   Google Scholar
• •Review of the possible physiological function of the group IIA PLA2.
   Google Scholar
• CHEN J, ENGLE SJ, SEILHAMER JJ, TISCHFIELD JA: Cloning and recombinant expression of a novel human low molecular weight Ca2+-dependent phospholipase A2. j Biol. Chem. (1994) 269(4):2365–2368.
   Google Scholar
• CHOW: Structure, function, and regulation of group V phospholipase A2. Biochim. Biophys. Acta. (2000) 1488(1-2):48–58.
   Google Scholar
• CUPILLARD L, KOUMANOV K, MATTEI MG, LAZDUNSKI M, LAMBEAU G: Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2. j Biol. Chem. (1997) 272(25):15745–15752.
   Google Scholar
• HANASAKI K, ONO T, SAIGA A et al.: Purified group X secretory phospholipase A2 induced prominent release of arachidonic acid from human myeloid leukemia cells. j Biol. Chem. (1999) 274(48):34203–34211.
   Google Scholar
• MORIOKA Y, SAIGA A, YOKOTA Y et al.: Mouse group X secretory phospholipase A2 induces a potent release of arachidonic acid from spleen cells and acts as a ligand for the phospholipase A2 receptor. Arch. Biochem. Biophys. (2000) 381(1):31–42.
   Google Scholar
• KATSUMATA M, GUPTA C, GOLDMAN AS: A rapid assay for activity of phospholipase A2 using radioactive substrate. Anal. Biochem. (1986) 154(2):676–681.
   Google Scholar
• BENNION C, CONNOLLY S, GENSMANTEL NP etal.: Design and synthesis of some substrate analogue inhibitors of phospholipase A2 and investigations by NMR and molecular modeling into the binding interactions in the enzyme-inhibitor complex. I Med. Chem. (1992) 35(16):2939–2951.
   Google Scholar
• LEMAHIEU RA, CARSON M, HAN RJ et al.: N-(carboxymethyl)-N-13,5-bis(decyloxy)-phenyllglycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activity. J. Med. Chem. (1993) 36(20):3029–3031.
   PubMedGoogle Scholar
• SUZUKI N, ISHIZAKI J, YOKOTA Y et al.: Structures, enzymatic properties, and expression of novel human and mouse secretory phospholipase A2s. I Biol. Chem. (2000) 275(8):5785–5793.
   Google Scholar
• KRAMER RIVI, ROBERTS EF, MANETTA J, PUTNAM JE: The Ca2+-sensitive cytosolic phospholipase A2 is a 100-kDa protein in human monoblast U937 cells. j Biol. Chem. (1991) 266(8):5268–5272.
   Google Scholar
• RADVANYI F, JORDAN L, RUSSO-MARIE E BON C: A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labeled phospholipids in the presence of serum albumin. Anal. Biochem. (1989) 177(1):103–109.
   Google Scholar
• BAYBURT T, YU BZ, STREET I et al.: Continuous, vesicle-based fluorimetric assays of 14- and 85-kDa phospholipases A2. Anal. Biochem. (1995) 232(1):7–23.
   Google Scholar
• HUANG Z, LALIBERTE ETREMBLAY NM, WEECH PK, STREET IP: A continuous fluorescence-based assay for the human high-molecular-weight cytosolic phospholipase A2. Anal. Biochem. (1994) 222(1):110–115.
   PubMedGoogle Scholar
• BLANCHARD SG, HARRIS CO, PARKS DJ: A fluorescence-based assay for human Type II phospholipase A2. Anal. Biochem. (1994) 222:435–440.
   Google Scholar
• REYNOLDS LJ, HUGHES LL, DENNIS EA: Analysis of human synovial fluid phospholipase A2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiterplate reader. Anal. Biochem. (1992) 204(1):190–197.
   PubMed Web of Science ®Google Scholar
• REYNOLDS LJ, HUGHES LL, YU L, DENNIS EA: 1-Hexadecy1-2-arachidonoylthio-2-deoxy-sn-glycero-3-phosphorylcholine as a substrate for the microtiterplate assay of human cytosolic phospholipase A2. Anal. Biochem. (1994) 217(1):25–32.
   PubMedGoogle Scholar
• TOJO H, ONO T, OKAMOTO M: Reverse-phase high-performance liquid chromatographic assay of phospholipases: application of spectrophotometric detection to rat phospholipase A2 isozymes. I Lipid Res. (1993) 34(5):837–844.
   Google Scholar
• GHOMASHCHI E LOO R, BALSINDE J etal.: Trifluoromethyl ketones and methyl fluorophosphonates as inhibitors of group IV and VI phospholipases A2: structure-function studies with vesicle, micelle, and membrane assays. Biochim. Biophys. Acta. (1999) 1420(1–2):45–56.
   Google Scholar
• BURKE JR, WITMER MR, ZUSIS FC et al.: Competitive, reversible inhibition of cytosolic phospholipase A2 at the lipid-water interface by choline derivatives that partially partition into the phospholipid bilayer. I Biol. Chem. (1999) 274(27):18864–18871.
   Google Scholar
• MARSHALL LA, CHANG JY: Pharmacological control of phospholipase A2 activity in vitro and in vivo. In: Phospholipase A0 Wong PYK, Dennis EA (Eds.), Plenum Press, New York (1990):169–182.
   Google Scholar
• KENNEDY B, PAYETTE P, RIENDEAU D, WEECH P, GRESSER M: Methyl arachidonyl fluorophosphonate, a potent irreversible cPLA2 inhibitor, blocks the mobilization of arachidonic acid in human platelets and neutrophils. Mediat. Irillamm. (1994) 3:307–308.
   Google Scholar
• LEHR M: In-vitro assay for the evaluationof phospholipase A2 inhibitors using bovine platelets and HPLC with UV-detection. Pharm. Pharmacol. Lett. (1992) 2(5):176–179.
   Google Scholar
• LEHR M, SCHULZE ELFRINGHOFF A: Comparison of the inhibition of the cytosolic phospholipase A2-mediated arachidonic acid release by several indole-2-carboxylic acids and 3-(pyrrol-2-y0propionic acids in bovine and in human platelets. Arch. Pharm. Pharm. Med. Chem. (2000) 333(9):312–316.
   Google Scholar
• RIENDEAU D, GUAY J, WEECH PK et al.: Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. j Biol. Chem. (1994) 269(22):15619–15624.
   PubMed Web of Science ®Google Scholar
• SENO K, OKUNO T, NISHI K et al.: Pyrrolidine inhibitors of human cytosolic phospholipase A2. j Med. Chem. (2000) 43(6):1041–1044.
   PubMed Web of Science ®Google Scholar
• SENO K, OKUNO T, NISHI K et al.: Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative `pyrrophenone'. Bioorg. Med. Chem. Lett. (2001) 11(4):587–90.
   Google Scholar
• METE A, AUSTIN R, BENNION C etal.: 1,3-Disubstituted propan-2-ones: a novel series of potent inhibitors of cytosolic phospholipase A2 (cPLA2). 15th EFMC International Symposium on Medicinal Chemistry Edinburgh, UK (1998) P250.
   Google Scholar
• •References 54–56 are publications on promising cPLA2 inhibitors.
   Google Scholar
• SATOSHI A, SHINGO M, KEISUKE K, HAYAMA M, SATO T: Involvement of group VI Ca2+-independent phospholipase A2 in protein kinase C-dependent arachidonic acid liberation in zymosan-stimulated macrophage-like P388D1 cells. Biol. Chem. (1999) 274(28):19906–19912.
   Google Scholar
• LEHR M, GRIESSBACH K: Involvement of different protein kinases and phospholipases A2 in phorbol ester (TPA)-induced arachidonic acid liberation in bovine platelets. Mediat. Inflamm. (2000) 9(1):31–34.
   Google Scholar
• GIJON MA, LESLIE CC: Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. I Leukocyte Biol. (1999) 65(3):330–336.
   PubMed Web of Science ®Google Scholar
• ARANZAZU PARTEARROYO M, OSTOLAZA H, GONI FM, BARBERA-GUILLEM E: Surfactant-induced cell toxicity and cell lysis. A study using B16 melanoma cells. Biochem. Pharmacol. (1990) 40(6):1323–1328.
   Google Scholar
• LEHR M: 3-(Octadecanoylaminomethyfl-indole-2-carboxylic acid derivatives and 1-methy1-3-octadecanoylindole-2-carboxylic acid as inhibitors of cytosolic phospholipase A2. Arch. Pharm. Pharm. Med. Chem. (1996) 329(8-9):386–392.
   Google Scholar
• LEHR M, GRIESSBACH K: Cell lytic and cPLA2-inhibitory properties in bovine platelets of the commercially available cPLA2 inhibitors, arachidonykrifluoromethyl ketone, methyl arachidonylfluorophosphonate and palmityltrifluoromethyl ketone. Pharm. Pharmacol. Commun. (1999) 5(6):389–393.
   Google Scholar
• TIBES U, VONDRAN A, RODEWALD E, FRIEBE WG, SCHAEFER W, SCHEUER W: Inhibition of allergic and non-allergic inflammation by phospholipase A2 inhibitors. Int. Arch. Allergy brimurrol. (1995) 107(1-3):432–434.
   Google Scholar
• BURGERMEISTER-AMANDI E, TIBES U, KAISER BM, FRIEBE WG, SCHEUER WV: Suppression of cytokine synthesis, intergrin expression and chronic inflammation by inhibitors of cytosolic phospholipase A2. Eur. Pharmacol. (1997) 326(2-3):237–250.
   Google Scholar
• TRIES S, NEHER K, LAUFER S, ABRAHAM WM, LEHR M: Effects of ML 3176, an inhibitor of cPLA2, on carrageenan-induced rat paw edema, phorbolester-induced mouse ear edema and in a sheep model of asthma. Mediat, Inflamm. (1999) 8\(Supp1.1):S123–S124.
   Google Scholar
• TRIES S, NEUPERT W, ALBRECHT W LEHR M, LAUFER S: Anti-inflammatory activity of cPLA2 inhibitors upon oral, intra peritoneal and dermal administration. 10th National Meeting of the Inflammation Research Association. Hot Springs, USA (2000).
   Google Scholar
• BLANCHARD SG, ANDREWS RC, BROWN PJ et al.: Discovery of bioavailable inhibitors of secretory phospholipase A2. Pharm. Biotechnol. (1998) 11:445–463.
   Google Scholar
• VADAS E SCOTT K, SMITH G etal.: Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock. Life Sci. (1992) 50(10:807–811.
   Google Scholar
• STEPHENSON D, RASH K, SMALSTIG B et al.: Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Clia (1999) 27(2):110–128.
   Google Scholar
• STEPHENSON DT, LEMERE CA, SELKOE DJ, CLEMENS JA: Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol. Dis. (1996) 3(1):51–63.
   Google Scholar
• STREET IP, LIN HK, LALIBERTE F et al.: Slow- and tight-binding inhibitors of the 85-kDA human phospholipase A2. Biochemistry (1993) 32(23):5935–5940.
   PubMed Web of Science ®Google Scholar
• SNYDER DW, BACH NJ, DILLARD RD et al.: Pharmacology of LY315920/S-5920, 113- (aminooxoacety1)-2-ethy1-1- (phenylmethyl)-1H-indo1-4-yll oxyl acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J. Pharmacol. Exp. Ther. (1999) 288(3):1117–1124.
   Google Scholar
• CHEN Y, DENNIS EA: Expression and characterization of human group V phospholipase A2. Biochim. Biophys. Acta. (1998) 1394(1):57–64.
   Google Scholar
• YOKOTA Y, HANASAKI K, ONO T, NAKAZATO H, KOBAYASHI T, ARITA H: Suppression of murine endotoxic shock by 5PLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms. Biochim. Biophys. Acta. (1999) 1438(2):213–222.
   PubMed Web of Science ®Google Scholar
• •Evidence that blockade of the PLA2 receptor could become a treatment option for the therapy of septic shock.
   Google Scholar
• HOECK WG, RAMESHA CS, CHANG DJ, FAN N, HELLER RA: Cytoplasmic phospholipase A2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis. Proc. Natl. Acad. Sci. USA (1993) 90(10)4475–4479.
   Google Scholar
• ANGEL J, BERENBAUM F, LE DENMAT C, NEVALAINEN T, MASLIAH J, FOURNIER C: Interleukin- 1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur. I Biochem. (1994) 226(1):125–131.
   Google Scholar
• HULKOWER KI, WERTHEIMER SJ, LEVIN W et al.: Interleukin-13 induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostaglandin E2. Arthritis Rheum. (1994) 37(5):653–661.
   Google Scholar
• DESSEN A, TANG J, SCHMIDT H et al.: Crystal structure of human cytosolic phospholipase A2 reveals a novel topology and catalytic mechanism. Cell (1999) 97(3):349–360.
   PubMed Web of Science ®Google Scholar
• •Information about structure and mechanism of cytosolic PLA2.
   Google Scholar